Base de dados : MEDLINE
Pesquisa : D20.215.784.500.720 [Categoria DeCS]
Referências encontradas : 583 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 59 ir para página                         

  1 / 583 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29185927
[Au] Autor:Ogata M; Ogita T; Tari H; Arakawa T; Suzuki T
[Ad] Endereço:1Department of Biofunctional Science and Technology,Graduate School of Biosphere Science,Hiroshima University,Higashi-Hiroshima, 739-8528,Japan.
[Ti] Título:Supplemental psyllium fibre regulates the intestinal barrier and inflammation in normal and colitic mice.
[So] Source:Br J Nutr;118(9):661-672, 2017 Nov.
[Is] ISSN:1475-2662
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Our previous study demonstrated that supplemental psyllium fibre increased cytoprotective heat-shock protein (Hsp) 25 levels in the intestinal cells of mice. Here, we examined the effect of psyllium fibre on colonic gene and protein expression and faecal microbiota in normal and colitic mice to improve the understanding of the preventive role of the supplement. DNA microarray analysis revealed that a 10 % psyllium fibre diet administered for 5 d up-regulated eleven extracellular matrix (ECM)-associated genes, including collagens and fibronectins, in normal mice. Acute colitis was induced using dextran sodium sulphate (DSS) in mice that were administered a pre-feeding 5 to 10 % psyllium fibre diet for 5 d. Psyllium fibre partially ameliorated or resolved the DSS-induced colon damage and inflammation characterised by body weight loss, colon shortening, increased levels of pro-inflammatory cytokines and decreased tight junction protein expression in the colon. Analysis of faecal microbiota using denaturing gradient gel electrophoresis of the PCR-amplified 16S rRNA gene demonstrated that psyllium fibre affected the colonic microbiota. Intestinal permeability was evaluated by growing intestinal Caco-2 cell monolayers on membrane filter supports coated with or without fibronectin and collagen. Cells grown on collagen and fibronectin coating showed higher transepithelial electrical resistance, indicating a strengthening of barrier integrity. Therefore, increased Hsp25 levels and modification of colonic ECM contribute to the observed psyllium-mediated protection against DSS-induced colitis. Furthermore, ECM modification appears to play a role in the strengthening of the colon barrier. In conclusion, psyllium fibre may be useful in the prevention of intestinal inflammatory diseases.
[Mh] Termos MeSH primário: Colite/tratamento farmacológico
Fibras na Dieta/farmacologia
Inflamação/tratamento farmacológico
Intestinos/efeitos dos fármacos
Psyllium/farmacologia
[Mh] Termos MeSH secundário: Animais
Células CACO-2
Colite/induzido quimicamente
Colágeno/farmacologia
Citocinas/sangue
DNA Bacteriano/isolamento & purificação
Sulfato de Dextrana
Matriz Extracelular/genética
Matriz Extracelular/metabolismo
Fezes/microbiologia
Fibronectinas/farmacologia
Microbioma Gastrointestinal/efeitos dos fármacos
Seres Humanos
Absorção Intestinal/efeitos dos fármacos
Intestinos/metabolismo
Masculino
Camundongos
Camundongos Endogâmicos BALB C
Camundongos Endogâmicos ICR
Permeabilidade/efeitos dos fármacos
RNA Ribossômico 16S/isolamento & purificação
Junções Íntimas/genética
Junções Íntimas/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Cytokines); 0 (DNA, Bacterial); 0 (Dietary Fiber); 0 (Fibronectins); 0 (RNA, Ribosomal, 16S); 8063-16-9 (Psyllium); 9007-34-5 (Collagen); 9042-14-2 (Dextran Sulfate)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171211
[Lr] Data última revisão:
171211
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171130
[St] Status:MEDLINE
[do] DOI:10.1017/S0007114517002586


  2 / 583 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28817614
[Au] Autor:Monge Neto AÁ; Bergamasco RC; de Moraes FF; Medina Neto A; Peralta RM
[Ad] Endereço:Postgraduate Program in Food Science, State University of Maringá, Maringá, Paraná, Brazil.
[Ti] Título:Development of a technique for psyllium husk mucilage purification with simultaneous microencapsulation of curcumin.
[So] Source:PLoS One;12(8):e0182948, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:This study focused on evaluating a technique for the psyllium husk mucilage (PHM) purification with simultaneous microencapsulation of curcumin. PHM was extracted with water and purified with ethanol. For the mucilage purification and simultaneous microencapsulation, an ethanolic solution of curcumin was used. After dehydration, the samples were analysed by instrumental techniques and evaluated for thermal stability. The presence of curcumin in the solution did not impair the yield of precipitated polysaccharide. Interactions of the dye and carbohydrates were confirmed by displacement of peaks in FT-IR and FT-Raman spectroscopy. The onset temperature of degradation of microcapsules was superior to that of curcumin. Thermal stability in solution at 90°C also improved. After 300 minutes of heating, the microcapsules had a remnant curcumin content exceeding 70%, while, in standard sample, the remaining curcumin content was 4.46%. Thus, the developed technique was successful on purification of PHM and microencapsulation of curcumin.
[Mh] Termos MeSH primário: Cápsulas/química
Curcumina/química
Extratos Vegetais/química
Mucilagem Vegetal/química
Psyllium/química
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Capsules); 0 (Plant Extracts); 0 (Plant Mucilage); 8063-16-9 (Psyllium); IT942ZTH98 (Curcumin)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171016
[Lr] Data última revisão:
171016
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170818
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0182948


  3 / 583 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28252255
[Au] Autor:Lambeau KV; McRorie JW
[Ad] Endereço:Employee and Community Health, Mayo Clinic, Rochester, Minnesota.
[Ti] Título:Fiber supplements and clinically proven health benefits: How to recognize and recommend an effective fiber therapy.
[So] Source:J Am Assoc Nurse Pract;29(4):216-223, 2017 Apr.
[Is] ISSN:2327-6924
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Only 5% of adults consume the recommended level of dietary fiber. Fiber supplements appear to be a convenient and concentrated source of fiber, but most do not provide the health benefits associated with dietary fiber. PURPOSE: This review will summarize the physical effects of isolated fibers in small and large intestines, which drive clinically meaningful health benefits. DATA SOURCES: A comprehensive literature review was conducted (Scopus and PubMed) without limits to year of publication (latest date included: October 31, 2016). CONCLUSIONS: The physical effects of fiber in the small intestine drive metabolic health effects (e.g., cholesterol lowering, improved glycemic control), and efficacy is a function of the viscosity of gel-forming fibers (e.g., psyllium, ß-glucan). In the large intestine, fiber can provide a laxative effect if (a) it resists fermentation to remain intact throughout the large intestine, and (b) it increases percentage of water content to soften/bulk stool (e.g., wheat bran and psyllium). IMPLICATIONS FOR PRACTICE: It is important for nurse practitioners to understand the underlying mechanisms that drive specific fiber-related health benefits, and which fiber supplements have rigorous clinical data to support a recommendation. CLINICAL PEARL: For most fiber-related beneficial effects, "Fiber needs to gel to keep your patients well."
[Mh] Termos MeSH primário: Fibras na Dieta/uso terapêutico
Suplementos Nutricionais/normas
Metabolismo/efeitos dos fármacos
Metabolismo/fisiologia
[Mh] Termos MeSH secundário: Fibras na Dieta/farmacologia
Glucanos/farmacologia
Glucanos/uso terapêutico
Seres Humanos
Intestino Delgado/fisiologia
Inulina/farmacologia
Inulina/uso terapêutico
Psyllium/farmacologia
Psyllium/uso terapêutico
beta-Glucanas/farmacocinética
beta-Glucanas/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Dietary Fiber); 0 (Glucans); 0 (beta-Glucans); 8063-16-9 (Psyllium); 9005-80-5 (Inulin); VH2XOU12IE (polydextrose)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:N
[Da] Data de entrada para processamento:170303
[St] Status:MEDLINE
[do] DOI:10.1002/2327-6924.12447


  4 / 583 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28244666
[Au] Autor:Halmos EP
[Ad] Endereço:Department of Gastroenterology, Central Clinical School, Monash University, Melbourne, Victoria, Australia.
[Ti] Título:When the low FODMAP diet does not work.
[So] Source:J Gastroenterol Hepatol;32 Suppl 1:69-72, 2017 Mar.
[Is] ISSN:1440-1746
[Cp] País de publicação:Australia
[La] Idioma:eng
[Ab] Resumo:Irritable bowel syndrome (IBS) is heterogeneous. Patients need proper assessment and explanation of IBS pathophysiology and appropriate therapies. A low FODMAP (fermentable oligosaccharides, disaccharides, monosaccharides, and polyols) diet effectively reduces symptoms in 75% of patients. Best treatment for those nonresponsive will depend on the pathophysiological basis for symptom genesis, with the following possible abnormalities: (i) Visceral hypersensitivity and/or enhanced gut-brain communication: a low FODMAP diet is mainly targeted for this patient group. A dietitian may also recommend antispasmodic agents, including peppermint oil. Another dietary treatment is a low food chemical diet, although this diet is often extremely limited, and therefore, not suited for some populations. Psychological therapies are also clinically beneficial. (ii) Altered motility: in patients with fast transit, a dietitian may recommend a reduction in all FODMAPs or targeted monosaccharides and disaccharides, which are more osmotic in nature. If not effective, patients may benefit from psyllium, which has an exceptional water-holding capacity aimed to promote more formed stools. Patients with slow or uncoordinated transit are often more difficult to treat. Dietary interventions have some success and usually comprise a combination of adequate fiber and fluid, osmotic laxatives, and stimulating agents such as caffeine, senna, and exercise. (iii) Altered microbiome: supplementary probiotics and prebiotics have weak evidence of efficacy with some notable exceptions. A dietitian may trial supplementary Bifidobacterium infantis or oligosaccharides, usually as an adjunct therapy. Guidance from a dietitian will encompass dietary methods to treat IBS but additionally identify where dietary treatment is not indicated to ensure that diet is correctly used and patients are not nutritionally or psychologically compromised.
[Mh] Termos MeSH primário: Dieta com Restrição de Carboidratos
Síndrome do Intestino Irritável/dietoterapia
[Mh] Termos MeSH secundário: Bifidobacterium longum subspecies infantis
Dissacarídeos/administração & dosagem
Dissacarídeos/efeitos adversos
Fermentação
Motilidade Gastrointestinal
Seres Humanos
Síndrome do Intestino Irritável/etiologia
Síndrome do Intestino Irritável/fisiopatologia
Laxantes/administração & dosagem
Monossacarídeos/administração & dosagem
Monossacarídeos/efeitos adversos
Oligossacarídeos/administração & dosagem
Oligossacarídeos/efeitos adversos
Parassimpatolíticos/administração & dosagem
Óleos Vegetais/administração & dosagem
Polímeros/administração & dosagem
Polímeros/efeitos adversos
Processos Psicoterapêuticos
Psyllium/administração & dosagem
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Disaccharides); 0 (Laxatives); 0 (Monosaccharides); 0 (Oligosaccharides); 0 (Parasympatholytics); 0 (Plant Oils); 0 (Polymers); 0 (polyol); 8063-16-9 (Psyllium); AV092KU4JH (peppermint oil)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170810
[Lr] Data última revisão:
170810
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170301
[St] Status:MEDLINE
[do] DOI:10.1111/jgh.13701


  5 / 583 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28146065
[Au] Autor:Pal S; Ho S; Gahler RJ; Wood S
[Ad] Endereço:School of Public Health, Curtin University, Perth 6845, Australia. s.pal@curtin.edu.au.
[Ti] Título:Effect on Insulin, Glucose and Lipids in Overweight/Obese Australian Adults of 12 Months Consumption of Two Different Fibre Supplements in a Randomised Trial.
[So] Source:Nutrients;9(2), 2017 Jan 29.
[Is] ISSN:2072-6643
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:Higher fibre intakes are associated with risk reduction for chronic diseases. This study investigated the effects of supplementation with PolyGlycopleX (PGX), a complexed polysaccharide, on insulin, glucose and lipids in overweight and obese individuals. In this double-blind 12 months study, participants were randomised into three groups: control (rice flour); PGX or psyllium (PSY). Participants followed their usual lifestyle and diet but consumed 5 g of their supplement before meals. Insulin was significantly lower in the PGX and PSY groups compared to control at 3 and 6 months and in the PSY group compared to control at 12 months. Serum glucose was significantly lower in the PGX group at 3 months compared to control. Total cholesterol was significantly lower in the PGX and PSY groups compared to control at 3 and 6 months. High density lipoprotein (HDL) cholesterol was significantly increased in the PGX group compared to control at 12 months. low density lipoprotein (LDL) cholesterol was significantly lower in the PGX group at 3 and 6 months compared to control and in the PSY group at 3 months compared to control. A simple strategy of fibre supplementation may offer an effective solution to glucose, insulin and lipid management without the need for other nutrient modification.
[Mh] Termos MeSH primário: Glicemia/metabolismo
Fibras na Dieta/administração & dosagem
Insulina/sangue
Lipídeos/administração & dosagem
Obesidade/sangue
Sobrepeso/sangue
[Mh] Termos MeSH secundário: Adulto
Alginatos/administração & dosagem
Composição Corporal
Índice de Massa Corporal
HDL-Colesterol/sangue
LDL-Colesterol/sangue
Dieta
Carboidratos da Dieta/administração & dosagem
Gorduras na Dieta/administração & dosagem
Proteínas na Dieta/administração & dosagem
Suplementos Nutricionais
Método Duplo-Cego
Combinação de Medicamentos
Exercício
Feminino
Seres Humanos
Masculino
Meia-Idade
Polissacarídeos Bacterianos/administração & dosagem
Psyllium/administração & dosagem
Triglicerídeos/sangue
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Alginates); 0 (Blood Glucose); 0 (Cholesterol, HDL); 0 (Cholesterol, LDL); 0 (Dietary Carbohydrates); 0 (Dietary Fats); 0 (Dietary Fiber); 0 (Dietary Proteins); 0 (Drug Combinations); 0 (Insulin); 0 (Lipids); 0 (PolyGlycoplex); 0 (Polysaccharides, Bacterial); 0 (Triglycerides); 8063-16-9 (Psyllium)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170202
[St] Status:MEDLINE


  6 / 583 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28054363
[Au] Autor:Zhong R; Yu Y; Zheng Y; Chen W; Zhou G; Ding J; Yuan M
[Ad] Endereço:Jiangxi Institute for Drug Control, Nanchang, People's Republic of China.
[Ti] Título:A simple and selective UHPLC-MS/MS method for quantification of plantagoguanidinic acid in rat plasma and its application to a pharmacokinetic study.
[So] Source:Biomed Chromatogr;31(8), 2017 Aug.
[Is] ISSN:1099-0801
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:A simple, sensitive and specific UHPLC-MS/MS method for quantification of plantagoguanidinic acid (PGA) in rat plasma was applied to investigate the pharmacokinetic behavior in vivo, using protopine as internal standard. The chromatography was separated on a Phenomenex® Luna-C column (2.1 × 150 mm, 3.0 µm) within 7.0 min using a mobile phase consisting of acetonitrile-0.1% formic acid solution under gradient elution at a flow rate of 0.4 mL/min. Prepared samples were monitored by multiple reaction monitoring mode, with the target fragmentions m/z 226.2 → 84.2 for PGA and m/z 354.2 → 188.9 for IS in positive electrospray ionization. The calibration curve of PGA was linear throughout the range 1-1000 ng/mL (r = 0.9962). The lower limit of quantitation in plasma for PGA was 0.1 ng/mL, and the recovery was >88.6%. Intra- and interday accuracy ranged from -8.6 to 4.9%. Furthermore, this validated method was successfully used for a pre-clinical pharmacokinetic study of PGA at a single dose of 20 and 5 mg/kg in rats via oral and intravenous administration. The study showed that PGA was absorpted rapidly and eliminated gradually with a greater absolute oral bioavailability of 70.1% in rats.
[Mh] Termos MeSH primário: Alcaloides/sangue
Anti-Inflamatórios/sangue
Cromatografia Líquida de Alta Pressão/métodos
Guanidinas/sangue
Hipoglicemiantes/sangue
Plantago/química
Espectrometria de Massas em Tandem/métodos
[Mh] Termos MeSH secundário: Administração Intravenosa
Administração Oral
Animais
Disponibilidade Biológica
Medicamentos de Ervas Chinesas/farmacocinética
Limite de Detecção
Masculino
Psyllium/química
Ratos Sprague-Dawley
[Pt] Tipo de publicação:JOURNAL ARTICLE; VALIDATION STUDIES
[Nm] Nome de substância:
0 (Alkaloids); 0 (Anti-Inflammatory Agents); 0 (Drugs, Chinese Herbal); 0 (Guanidines); 0 (Hypoglycemic Agents); 0 (plantagoguanidinic acid); 8063-16-9 (Psyllium)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170726
[Lr] Data última revisão:
170726
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170106
[St] Status:MEDLINE
[do] DOI:10.1002/bmc.3929


  7 / 583 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27987136
[Au] Autor:Prasad VG; Abraham P
[Ad] Endereço:VGM Hospital, 2100, Trichy Road, Coimbatore, 641 005, India. drvgm@rediffmail.com.
[Ti] Título:Management of chronic constipation in patients with diabetes mellitus.
[So] Source:Indian J Gastroenterol;36(1):11-22, 2017 Jan.
[Is] ISSN:0975-0711
[Cp] País de publicação:India
[La] Idioma:eng
[Ab] Resumo:AIM: The aim of this review is to provide an overview of the clinical assessment and evidence-based treatment options for managing diabetes-associated chronic constipation. METHODS: A literature search of published medical reports in English language was performed using the OVID Portal, from PUBMED and the Cochrane Database of Systematic Reviews, from inception to October 2015. A total of 145 abstracts were identified; duplicate publications were removed and 95 relevant full-text articles were retrieved for potential inclusion. RESULTS: Chronic constipation is one of the most common gastrointestinal symptoms in patients with diabetes, and occurs more frequently than in healthy individuals. Treatment goals include improving symptoms and restoring bowel function by accelerating colonic transit and facilitating defecation. Based on guidelines and data from published literature, food and dietary change with exercise and lifestyle change should be the first step in management. For patients recalcitrant to these changes, laxatives should be the next step of treatment. Treatment should begin with bulking agents such as psyllium, bran or methylcellulose followed by osmotic laxatives if response is poor. Lactulose, polyethylene glycol and lactitol are the most frequently prescribed osmotic agents. Lactulose has a prebiotic effect and a carry-over effect (continued laxative effect for at least 6 to 7 days, post cessation of treatment). Stimulants such as bisacodyl, sodium picosulphate and senna are indicated if osmotic laxatives are not effective. Newer agents such as chloride-channel activators and 5-HT4 agonist can be considered for severe or resistant cases. CONCLUSION: The primary aim of intervention in diabetic patients with chronic constipation is to better manage the diabetes along with management of constipation. The physician should explain the rationale for prescribing laxatives and educate patients about the potential drawbacks of long-term use of laxatives. They should contact their physician if short-term use of prescribed laxative fails to provide relief.
[Mh] Termos MeSH primário: Constipação Intestinal/etiologia
Constipação Intestinal/terapia
Complicações do Diabetes/complicações
[Mh] Termos MeSH secundário: Bisacodil/administração & dosagem
Agonistas dos Canais de Cloreto/administração & dosagem
Doença Crônica
Citratos/administração & dosagem
Fibras na Dieta/administração & dosagem
Medicina Baseada em Evidências
Terapia por Exercício
Estilo de Vida Saudável
Seres Humanos
Laxantes/administração & dosagem
Metilcelulose/administração & dosagem
Compostos Organometálicos/administração & dosagem
Picolinas/administração & dosagem
Psyllium/administração & dosagem
Extrato de Sena/administração & dosagem
Agonistas de Receptores 5-HT4 de Serotonina/administração & dosagem
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Chloride Channel Agonists); 0 (Citrates); 0 (Dietary Fiber); 0 (Laxatives); 0 (Organometallic Compounds); 0 (Picolines); 0 (Serotonin 5-HT4 Receptor Agonists); 10X0709Y6I (Bisacodyl); 8013-11-4 (Senna Extract); 8063-16-9 (Psyllium); 9004-67-5 (Methylcellulose); LR57574HN8 (picosulfate sodium)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161218
[St] Status:MEDLINE
[do] DOI:10.1007/s12664-016-0724-2


  8 / 583 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27863994
[Au] Autor:McRorie JW; McKeown NM
[Ti] Título:Understanding the Physics of Functional Fibers in the Gastrointestinal Tract: An Evidence-Based Approach to Resolving Enduring Misconceptions about Insoluble and Soluble Fiber.
[So] Source:J Acad Nutr Diet;117(2):251-264, 2017 Feb.
[Is] ISSN:2212-2672
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Enduring misconceptions about the physical effects of fiber in the gut have led to misunderstandings about the health benefits attributable to insoluble and soluble fiber. This review will focus on isolated functional fibers (eg, fiber supplements) whose effects on clinical outcomes have been readily assessed in well-controlled clinical studies. This review will also focus on three health benefits (cholesterol lowering, improved glycemic control, and normalizing stool form [constipation and diarrhea]) for which reproducible evidence of clinical efficacy has been published. In the small bowel, clinically meaningful health benefits (eg, cholesterol lowering and improved glycemic control) are highly correlated with the viscosity of soluble fibers: high viscosity fibers (eg, gel-forming fibers such as b-glucan, psyllium, and raw guar gum) exhibit a significant effect on cholesterol lowering and improved glycemic control, whereas nonviscous soluble fibers (eg, inulin, fructooligosaccharides, and wheat dextrin) and insoluble fibers (eg, wheat bran) do not provide these viscosity-dependent health benefits. In the large bowel, there are only two mechanisms that drive a laxative effect: large/coarse insoluble fiber particles (eg, wheat bran) mechanically irritate the gut mucosa stimulating water and mucous secretion, and the high water-holding capacity of gel-forming soluble fiber (eg, psyllium) resists dehydration. Both mechanisms require that the fiber resist fermentation and remain relatively intact throughout the large bowel (ie, the fiber must be present in stool), and both mechanisms lead to increased stool water content, resulting in bulky/soft/easy-to-pass stools. Soluble fermentable fibers (eg, inulin, fructooligosaccharide, and wheat dextrin) do not provide a laxative effect, and some fibers can be constipating (eg, wheat dextrin and fine/smooth insoluble wheat bran particles). When making recommendations for a fiber supplement, it is essential to recognize which fibers possess the physical characteristics required to provide a beneficial health effect, and which fiber supplements are supported by reproducible, rigorous evidence of one or more clinically meaningful health benefits.
[Mh] Termos MeSH primário: Fibras na Dieta/administração & dosagem
Medicina Baseada em Evidências
Trato Gastrointestinal/metabolismo
[Mh] Termos MeSH secundário: Glicemia/metabolismo
Colesterol/sangue
Fezes/química
Galactanos/administração & dosagem
Seres Humanos
Inulina/administração & dosagem
Laxantes/administração & dosagem
Mananas/administração & dosagem
Gomas Vegetais/administração & dosagem
Psyllium/administração & dosagem
Ensaios Clínicos Controlados Aleatórios como Assunto
Viscosidade
beta-Glucanas/administração & dosagem
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Blood Glucose); 0 (Dietary Fiber); 0 (Galactans); 0 (Laxatives); 0 (Mannans); 0 (Plant Gums); 0 (beta-Glucans); 8063-16-9 (Psyllium); 9005-80-5 (Inulin); 97C5T2UQ7J (Cholesterol); E89I1637KE (guar gum)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:161120
[St] Status:MEDLINE


  9 / 583 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27355265
[Au] Autor:Okuda Y; Taura K; Yoshino K; Ikeno Y; Nishio T; Yamamoto G; Tanabe K; Koyama Y; Hatano E; Tanaka S; Uemoto S
[Ad] Endereço:*Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan †Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University, Kyoto, Japan.
[Ti] Título:Usefulness of Mac-2 Binding Protein Glycosylation Isomer for Prediction of Posthepatectomy Liver Failure in Patients With Hepatocellular Carcinoma.
[So] Source:Ann Surg;265(6):1201-1208, 2017 Jun.
[Is] ISSN:1528-1140
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: The aim of this study was to evaluate the usefulness of the Mac-2 binding protein glycosylation isomer (M2BPGi) for the prediction of posthepatectomy liver failure (PHLF) in hepatocellular carcinoma (HCC) patients. SUMMARY BACKGROUND DATA: M2BPGi is a novel serum marker of liver fibrosis. The usefulness of M2BPGi for the prediction of PHLF has not been evaluated. METHODS: Clinicopathological data were analyzed in 138 HCC patients who underwent liver resection between August 2011 and November 2014. PHLF was evaluated according to the definition of the International Study Group of Liver Surgery. Performance of preoperative parameters in predicting PHLF was determined using receiver operating characteristic (ROC) analysis. RESULTS: Serum M2BPGi level correlated with the METAVIR fibrosis score. M2BPGi levels of hepatitis C virus (HCV)-positive patients were significantly higher than those of HCV-negative patients, even in the same fibrosis stage. PHLF ≥ Grade B developed in 19 patients (13.8%). The area under the ROC curve (AUROC) of M2BPGi for the prediction of PHLF ≥ Grade B was 0.71. In multivariate analysis, M2BPGi [odds ratio (OR): 2.08, 95% confidence interval (CI) 1.28-3.55], platelet count (OR: 0.39, 95% CI 0.18-0.80), and resection rate (OR: 2.71, 95% CI 1.46-5.40) were the significant factors associated with PHLF ≥ Grade B. The AUROC of the PHLF index defined by these factors was 0.81. Notably, in patients with HCV infection, the predictive ability of M2BPGi for PHLF (AUROC 0.85) was the best among the preoperative parameters. CONCLUSIONS: M2BPGi is a useful predictor of PHLF, especially in patients with HCV infection.
[Mh] Termos MeSH primário: Antígenos de Neoplasias/sangue
Carcinoma Hepatocelular/cirurgia
Hepatectomia/efeitos adversos
Falência Hepática/diagnóstico
Neoplasias Hepáticas/cirurgia
Glicoproteínas de Membrana/sangue
Complicações Pós-Operatórias/diagnóstico
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Biomarcadores/sangue
Combinação de Medicamentos
Feminino
Glicosilação
Seres Humanos
Cirrose Hepática/diagnóstico
Masculino
Meia-Idade
Psyllium
Estudos Retrospectivos
Extrato de Sena
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antigens, Neoplasm); 0 (Biomarkers); 0 (Drug Combinations); 0 (Membrane Glycoproteins); 0 (Perdiem); 0 (TAA90K protein, human); 8013-11-4 (Senna Extract); 8063-16-9 (Psyllium)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170720
[Lr] Data última revisão:
170720
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:160630
[St] Status:MEDLINE
[do] DOI:10.1097/SLA.0000000000001836


  10 / 583 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:27733202
[Au] Autor:Kaikkonen R; Niinistö K; Lindholm T; Raekallio M
[Ad] Endereço:Oulu Equine Clinic (Previously Evidensia Equine Clinic Oulu), Äimänrautiontie 5, 90400, Oulu, Finland. ritukaikkonen@gmail.com.
[Ti] Título:Comparison of psyllium feeding at home and nasogastric intubation of psyllium and magnesium sulfate in the hospital as a treatment for naturally occurring colonic sand (geosediment) accumulations in horses: a retrospective study.
[So] Source:Acta Vet Scand;58(1):73, 2016 Oct 12.
[Is] ISSN:1751-0147
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Ingestion of geosediment (further referred as sand) may cause weight loss, diarrhea and acute or recurrent colic in horses. Our aim was to compare the efficacy of three treatment protocols in clearing colonic sand accumulations in clinical patients. This retrospective clinical study consisted of 1097 horses and ponies, which were radiographed for the presence of colonic sand. Horses included to the study (n = 246) were displaying areas of sand in the radiographs of ≥75 cm and were treated medically monitoring the response with radiographs. The horses were assigned into three groups based on the given treatment: Group 1 was fed psyllium [1 g/kg body weight (BW)] daily at home for a minimum of 10 days (n = 57); Group 2 was treated once with psyllium or magnesium sulfate by nasogastric tubing followed by daily feeding of psyllium (1 g/kg BW) at home for a minimum of 10 days (n = 19), and Group 3 was treated by daily nasogastric tubing for 3-7 days with psyllium and/or magnesium sulfate (1 g of each/kg BW) (n = 170). RESULTS: The initial area of sand did not differ significantly between the treatments. Group 3 had significantly less residual sand than Groups 1 and 2, and the proportion of resolved horses was higher in Group 3 than in Groups 1 and 2. CONCLUSIONS: Daily nasogastric tubing with psyllium and/or magnesium sulfate for 3-7 days removes large accumulations of sand from the colon in horses more effectively than feeding psyllium for at least 10 days.
[Mh] Termos MeSH primário: Catárticos/administração & dosagem
Doenças dos Cavalos/tratamento farmacológico
Obstrução Intestinal/veterinária
Intubação Gastrointestinal/veterinária
Sulfato de Magnésio/administração & dosagem
Psyllium/administração & dosagem
[Mh] Termos MeSH secundário: Animais
Colo/patologia
Combinação de Medicamentos
Sedimentos Geológicos
Cavalos
Obstrução Intestinal/diagnóstico por imagem
Obstrução Intestinal/tratamento farmacológico
Radiografia/veterinária
Estudos Retrospectivos
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Cathartics); 0 (Drug Combinations); 7487-88-9 (Magnesium Sulfate); 8063-16-9 (Psyllium)
[Em] Mês de entrada:1701
[Cu] Atualização por classe:170220
[Lr] Data última revisão:
170220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161014
[St] Status:MEDLINE



página 1 de 59 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde